PCVX
Vaxcyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$63.68
+0.09%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$2.11
- Revenue estimate
- $12.5M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$1.97
- EPS estimate
- -$2.06
- Revenue actual
- —
- Revenue estimate
- $12.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -17.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $117
- PT range
- $89 – $130
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$2.06 | -$1.97 | Beat 4.37% | — |
| May 6, 2026 | -$1.77 | -$2.30 | Miss -29.65% | — |
| Feb 24, 2026 | -$1.46 | -$1.80 | Miss -23.29% | — |
| Nov 4, 2025 | -$1.27 | -$1.56 | Miss -22.83% | — |
| Aug 6, 2025 | -$1.12 | -$1.22 | Miss -8.93% | — |
| May 7, 2025 | -$1.02 | -$1.04 | Miss -1.96% | — |
| Feb 27, 2024 | -$0.90 | -$1.82 | Miss -102.22% | $14.4M |
| Feb 27, 2023 | -$0.84 | -$0.73 | Beat 13.10% | — |
| Feb 28, 2022 | -$0.46 | -$0.54 | Miss -17.39% | — |
| Nov 10, 2021 | -$0.47 | -$0.51 | Miss -8.51% | — |
| Aug 11, 2021 | -$0.46 | -$0.46 | In line | — |
| Nov 12, 2020 | -$0.42 | -$0.41 | Beat 2.38% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026